Skip to main content
Premium Trial:

Request an Annual Quote

IBM and Spotfire Announce Alliance, Sign Aventis as First Client for Combined Offering

NEW YORK, June 25 - IBM and Spotfire said Monday they would work together to combine Spotfire's software with IBM's back-end information management, data integration, and computing infrastructure. 

The companies also said that Aventis would be the first customer to use this combination of Spotfire's DecisionSite analysis platform and IBM's DiscoveryLink integration middleware. 

Financial terms for the partnerships were not disclosed.

Under the IBM/Spotfire alliance, Spotfire will optimize its current and future applications for IBM platforms and middleware, including the DB2 database and DiscoveryLink.

Aventis will use DiscoveryLink to manage and integrate data from multiple biological and chemical databases and will use DecisionSite to allow researchers to query those databases and identify new drug targets. The company said it expects this combination of techniques to reduce its drug innovation and approval from 10-15 years to six to nine years.

Spotfire also has partnerships to integrate DecisionSite with products from Micromass and Celera, while IBM has partnerships to integrate DiscoveryLink with products from Micromass, LabBook, and NetGenics.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.